DDIT3 and mantle cell lymphoma: The present study showed efficacy results similar to those (CR rates of 67.8% and 70.0% for iNHL and MCL, respectively) from phase 2 clinical study of original BDM 90 mg/m2/day and rituximab 375 mg/m2 in Japanese patients with treatment-naïve iNHL or MCL conducted by Ogura et al. [20] and those (CR rates of 40% and 30% for the bendamustine plus rituximab group and the R-CHOP group, respectively) from a phase 3 noninferiority study in patients with iNHL and mantle-cell lymphomas conducted by Rummel et al. [23].